• 90 Lisburn Road

    United Kingdom

Willing to speak to media

1991 …2019
If you made any changes in Pure these will be visible here soon.

Personal profile

Research Statement

My main focus is Cystic Fibrosis focused on understanding pathophysiology of infection and inflammation and the translation of new therapies into clinical practice. This programme of work is undertaken with laboratory and clinical collaborators in QUB. This includes a significant commitment from the NICRN (Respiratory Health) where I am PI on 6 current clinical trials. I have smaller programmes with others in COPD, bronchiectasis, lung cancer including clinical trials. My research is funded by grants from government agencies, charitable bodies, industry and money raised from clinical trials. I have developed a clinical trials network for Respiratory Health funded by the Northern Ireland Research and Development Office.

In all my research I endeavour to bring scientists and clinicians together to promote inter-disciplinary research. I have been successful in developing programmes of research across disciplines, hospitals and universities in Northern Ireland and across the UK and Europe.

Fingerprint Dive into the research topics where Stuart Elborn is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 35 Similar Profiles
Cystic Fibrosis Medicine & Life Sciences
Lung Medicine & Life Sciences
Sputum Medicine & Life Sciences
Bronchiectasis Medicine & Life Sciences
Pseudomonas aeruginosa Medicine & Life Sciences
Microbiota Medicine & Life Sciences
Anti-Bacterial Agents Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2009 2017

Selected Research Output 1991 2019

1077 Citations (Scopus)

A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation

Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Drevinek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., Moss, R., Ratjen, F., Sermet-Gaudelus, I., Rowe, S. M., Dong, Q., Rodriguez, S., Yen, K., Ordonez, C. & Elborn, J. S., 03 Nov 2011, In : New England Journal of Medicine. 365, 18, p. 1663-1672 10 p.

Research output: Contribution to journalArticle

Open Access
Cystic Fibrosis Transmembrane Conductance Regulator
Cystic Fibrosis
300 Citations (Scopus)

Detection of Anaerobic Bacteria in High Numbers in Sputum from Patients with Cystic Fibrosis

Tunney, M. M., Field, T. R., Moriarty, T. F., Patrick, S., Doering, G., Muhlebach, M. S., Wolfgang, M. C., Boucher, R., Gilpin, D. F., McDowell, A. & Elborn, J. S., 01 May 2008, In : American Journal of Respiratory and Critical Care Medicine. 177, 9, p. 995-1001 7 p.

Research output: Contribution to journalArticle

Anaerobic Bacteria
Cystic Fibrosis
Bacteriological Techniques
122 Citations (Scopus)

Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis

Tunney, M. M., Klem, E. R., Fodor, A. A., Gilpin, D. F., Moriarty, T. F., McGrath, S. J., Muhlebach, M. S., Boucher, R. C., Cardwell, C., Doering, G., Elborn, J. S. & Wolfgang, M. C., Jul 2011, In : Thorax. 66, 7, p. 579-584 6 p.

Research output: Contribution to journalArticle

Cystic Fibrosis
Anti-Bacterial Agents
Anaerobic Bacteria
69 Citations (Scopus)

Incidence and risk factors for pulmonary exacerbation treatment failures in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa

Parkins, M. D., Rendall, J. C. & Elborn, S., Feb 2012, In : Chest. 141, 2, p. 485-493 9 p.

Research output: Contribution to journalArticle

Treatment Failure
Cystic Fibrosis
Pseudomonas aeruginosa


Improving outcomes for people with cystic fibrosis through evidence based clinical trials

Stuart Elborn (Participant), Lorraine Martin (Participant), Damian Downey (Participant), Simon Brockbank (Participant), Madeleine Ennis (Participant)

Impact: Health Impact, Quality of Life Impact